Doc Logic,
I'll have to disagree about the partnership being a mandatory. Don't get me wrong, there will very probably be other companies that co-sponsor trials with NWBO, but I don't see them taking a position in NWBO, so I'd consider that a collaboration, but not truly a partnership. I say this because I don't believe that LP will agree to a partnership in which the partner has a serious ownership position in the company at under $20 a share, and no BP's going to pay substantially more than twice the current share price.
I believe that we'll have a many things happening before we reach a share price around $10. To begin with, beyond the acceptance of our MAA, we should have an Annual Meeting soon. At the Annual Meeting, I would think we'd get an update on the status of the EDEN unit, and some sort of guidance on when the company intends to approach the other regulators. We should get some news on the planning of new trials with both DCVax's. In short we'll learn a lot about what's planned to happen in the future, then we'll get approval from the UK, and with all of that our share price should grow. Perhaps at this time we should start new trials, and there we may have co-sponsors who're paying at least some of the costs.
I believe that this would be quite a bit of news, and should certainly bring our share price to the $5 range, or more. If by that time we're filing with one or more of the other regulators it could go substantially higher, if we're using the EDEN for commercial production, higher still. In short if all this has occurred it may be very possible that our share price is in the $10 or greater range, then we could be ready for that equity partnership with a BP. It won't happen overnight, but it could be this year. Let's see what's revealed when the company holds it's Annual Meeting, we should get some idea how close we're getting to this sort of success.
Gary
